Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cance...( - Results Demonstrating 95 Percent o...),Health

- Results Demonstrating 95 Percent or Greater Concordance Compared to FISH

and IHC Presented at 2008 ASCO Breast - - Company to Include Reporting for HER2 Gene Expression in All Oncotype DX

Reports by End of 2008 -

REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two studies demonstrating that quantitative reporting for HER2 gene expression, as measured by the company's Oncotype DX(R) breast cancer assay, has a high degree of concordance with both fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) testing. HER2 is an important marker for therapeutic decision-making for patients with breast cancer, and its measurement significantly impacts the chosen course of treatment. The research was presented at the ASCO Breast Cancer Symposium, September 5-8, 2008, in Washington, D.C.

"Many clinicians who already rely on the Recurrence Score(R) result for treatment planning have specifically requested that we provide the quantitative measure of HER2 gene expression in Oncotype DX reports," said Steven Shak, M.D., chief medical officer of Genomic Health. "Based on this research demonstrating the accuracy and reliability of HER2 measurement using RT-PCR, Oncotype DX can provide additional patient-specific information and insight into each patient's individual tumor biology."

Oncotype DX uses reverse transcription-polymerase chain reaction (RT-PCR) technology to quantify gene expression of 21 genes, one of which is HER2. The two studies found high concordance for testing with Oncotype DX compared to FISH (97 percent) and IHC (95 percent). Earlier this year, Genomic Health increased the clinical
'/>"/>